Adenosine receptor agonists

被引:27
作者
Jacobson, MA [1 ]
机构
[1] Merck Res Labs, Dept Neurosci, West Point, PA 19486 USA
关键词
A(1) adenosine receptor; A(2A) adenosine receptor; A(2B) adenosine receptor; A(3) adenosine receptor; agonists;
D O I
10.1517/13543776.12.4.489
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Adenosine, a naturally-occurring nucleoside, modulates a variety of physiological and pathophysiological processes. The effects of adenosine are mediated via a family of cell surface G-protein-coupled receptors designated into four subtypes, A, A(2A), A(2B), and A(3). The adenosine receptors have widespread tissue distribution and are often co-expressed in the same cell type. Research on adenosine receptors over the past few decades has resulted in the molecular cloning of the four subtypes from multiple species, significant progress in identifying selective agonists and antagonists and an increased understanding of the particular roles adenosine receptor subtypes play in physiological processes. This knowledge has continued to fuel considerable interest in pursuing adenosine receptors as therapeutic targets. For example, adenosine receptor agonists have been proposed for the treatment of heart arrhythmias, inflammatory diseases and in diagnosing coronary artery disease. In general, adenosine receptor agonists are derivatives of the physiological agonist, adenosine. The development of adenosine receptor agonists has been limited by an essential requirement for retention of the ribose moiety for agonist activity. Despite this restriction, significant progress has been made in the identification of potent and selective adenosine receptor agonists, some of which have entered clinical trials.
引用
收藏
页码:489 / 501
页数:13
相关论文
共 76 条
[1]  
Baraldi PG, 2000, MED RES REV, V20, P103, DOI 10.1002/(SICI)1098-1128(200003)20:2<103::AID-MED1>3.0.CO
[2]  
2-X
[3]   Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5′-N-ethyluronamide as A1 and A3 adenosine receptor agonists [J].
Baraldi, PG ;
Cacciari, B ;
de Las Infantas, MJP ;
Romagnoli, R ;
Spalluto, G ;
Volpini, R ;
Costanzi, S ;
Vittori, S ;
Cristalli, G ;
Melman, N ;
Park, KS ;
Ji, XD ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (17) :3174-3185
[4]   A1 and A3 adenosine receptor agonists:: an overview [J].
Baraldi, PG ;
Cacciari, B ;
Romagnoli, R ;
Spalluto, G .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (05) :515-527
[5]  
BAYLOR COLL MED, 2000, Patent No. 6026317
[6]  
BAYS DE, 1999, Patent No. 9967262
[7]  
CANFITE TECH LTD, 2001, Patent No. 0119360
[8]   2-ALKYNYL DERIVATIVES OF ADENOSINE AND ADENOSINE-5'-N-ETHYLURONAMIDE AS SELECTIVE AGONISTS AT A2 ADENOSINE RECEPTORS [J].
CRISTALLI, G ;
ELEUTERI, A ;
VITTORI, S ;
VOLPINI, R ;
LOHSE, MJ ;
KLOTZ, KN .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (13) :2363-2368
[9]  
CV THERAPEUTICS INC, 2001, Patent No. 0140246
[10]  
CV THERAPEUTICS INC, 2000, Patent No. 0078777